Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Phase 2

Terminated

Conditions: Prolymphocytic Leukemia

First Posted Date: 2006-01-25

Last Posted Date: 2016-09-26

Lead Sponsor: German CLL Study Group

Target Recruit Count: 21

Registration Number: NCT00281931

Locations: 🇩🇪
Helios Klinikum Erfurt, Erfurt, Germany

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Phase 2

Terminated

Conditions: Unusual Cancers of Childhood
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: busulfan
Drug: carmustine
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: cytarabine
Drug: mycophenolate mofetil
Drug: etoposide
Drug: methylprednisolone
Drug: tacrolimus
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 200

Registration Number: NCT00281879

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: alemtuzumab
Biological: anti-thymocyte globulin
Biological: filgrastim
Biological: rituximab
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-01-25

Last Posted Date: 2017-07-24

Lead Sponsor: German CLL Study Group

Target Recruit Count: 100

Registration Number: NCT00281983

Locations: 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
University Hospital of Leipzig, Leipzig, Germany
🇩🇪
Klinikum der Universitaet Regensburg, Regensburg, Germany

and more 10 locations

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2006-01-20

Last Posted Date: 2016-02-04

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 65

Registration Number: NCT00280241

Locations: 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Phase 2

Completed

Conditions: Prolymphocytic Leukemia

First Posted Date: 2006-01-18

Last Posted Date: 2018-05-11

Lead Sponsor: German CLL Study Group

Target Recruit Count: 17

Registration Number: NCT00278213

Locations: 🇦🇹
Allgemeines Krankenhaus - Universitatskliniken, Vienna, Austria
🇦🇹
Hanuschkrankenhaus, Vienna, Austria
🇩🇪
Allgemeinen Krankenhaus Celle Kinderklinik, Celle, Germany

and more 16 locations

Hematopoietic Stem Cell Support in Vasculitis

Phase 1

Terminated

Conditions: Vasculitis

Interventions: Biological: Autologous Stem Cell Transplant
Biological: Allogeneic Stem Cell Transplant
Drug: Cyclophosphamide
Drug: ATG (rabbit)
Drug: Campath-1h
Drug: G-CSF
Drug: Fludarabine
Drug: Mesna
Drug: Tacrolimus

First Posted Date: 2006-01-18

Last Posted Date: 2018-08-02

Lead Sponsor: Northwestern University

Target Recruit Count: 7

Registration Number: NCT00278512

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2006-01-13

Last Posted Date: 2016-09-26

Lead Sponsor: German CLL Study Group

Target Recruit Count: 30

Registration Number: NCT00276809

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪
Universitatsklinikum Heidelberg, Heidelberg, Germany
🇩🇪
University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 9 locations

Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine plus Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2006-01-13

Last Posted Date: 2019-05-23

Lead Sponsor: German CLL Study Group

Target Recruit Count: 375

Registration Number: NCT00276848

Locations: 🇩🇪
St. Marienhospital - Vechta, Vechta, Germany
🇩🇪
Evangelisches Krankenhaus Essen Werden, Essen, Germany
🇩🇪
Klinikum Frankfurt (Oder) GmbH, Frankfurt, Germany

and more 130 locations

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: filgrastim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-01-11

Last Posted Date: 2018-05-11

Lead Sponsor: German CLL Study Group

Target Recruit Count: 169

Registration Number: NCT00275015

Locations: 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany
🇩🇪
Internistische Praxis - Trier, Trier, Germany

and more 50 locations

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: aldesleukin
Biological: therapeutic allogeneic lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: in vitro treated peripheral blood stem cell transplantation

First Posted Date: 2006-01-11

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 21

Registration Number: NCT00274846

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy